Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. reported that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status in the United Arab Emirates for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors. This is the first international regulatory clearance for NEO212 following completion of Phase 1 evaluation.
The Phase 1 dose-escalation study established 610 mg as the recommended Phase 2 dose and showed early signs of clinical activity in heavily pretreated patients with recurrent glioblastoma and brain metastases. The new authorization is expected to support advancement into Phase 2 in the UAE, alongside ongoing U.S. FDA discussions on a potential registrational pathway.
Before enrolling patients in the UAE, NeOnc must obtain DOH Institutional Review Board approval and update its study documents and labeling. The clearance covers clinical research only and is not a marketing authorization. NeOnc has also applied in Abu Dhabi for several NEO100 programs, aiming to expand its brain cancer and neurological pipeline internationally.
NeOnc Technologies Holdings, Inc. is registering 555,554 shares of Common Stock for resale by a selling stockholder, consisting of 277,777 issued shares and 277,777 shares issuable upon exercise of a five-year Warrant. The Company will not receive proceeds from resales; proceeds only arise if the Warrant is exercised for cash.
The prospectus states 25,933,365 shares outstanding as of June 12, 2026 and cites a last reported Nasdaq sale price of $4.75 per share as of June 12, 2026. The resale registration covers shares issued under a private placement and the related Warrant with a $9.00 initial exercise price and beneficial ownership exercise limits (4.99%/9.99%).
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement with accredited investors to sell up to $5,000,000 of Series A Convertible Preferred Stock in a private placement. Up to 6,000 preferred shares will be issued at $833.34 per share, each with a stated value of $1,000.
The preferred stock ranks senior to common stock in a liquidation and carries no general voting rights. The company may redeem all Series A shares at stated value within four months, with two one‑month extension options that each add $50 per share. If the company elects not to redeem, an additional $166.67 per share is added and the shares become convertible into common stock at 80% of the lowest closing price over the prior five trading days, subject to a $1.00 floor, a 19.99% conversion cap without stockholder approval, and a beneficial ownership limit of 4.99% or 9.99% per holder.
NeOnc Technologies Holdings, Inc. is soliciting proxies for its virtual Annual Meeting of Stockholders to be held on August 14, 2026 at 10:00 a.m. Pacific Daylight Time. The Board fixed June 15, 2026 as the record date for voting.
The meeting agenda includes the election of two Class I directors, approval of a Plan Amendment, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm, and an adjournment proposal. Voting instructions, internet and telephone voting procedures, and proxy access rules are described herein.
NeOnc Technologies Holdings used this report to share first quarter 2026 results and progress in its brain cancer programs. For the quarter ended March 31, 2026, GAAP net loss was $8.8 million, and non-GAAP normalized cash operating expenses were $6.1 million.
Clinically, the company completed Phase 1 dose escalation for NEO212 and set 610 mg as the recommended Phase 2 dose, while its Phase 2a NEO100 study moves toward an interim readout supported by previously reported 24% radiographic remission and 44% six‑month progression-free survival. NeOnc also arranged a $10 million PIPE financing led by Cinctive Capital and noted an open‑market insider share purchase of more than $500,000.
NEONC Technologies Holdings, Inc. Schedule 13G reports that Cinctive Capital Management LP, Cinctive GP LLC and principals Richard H. Schimel and Lawrence J. Sapanski may each be deemed beneficial owners of 2,483,980 shares of Common Stock as of March 31, 2026.
The 2,483,980 figure consists of 1,425,526 shares of Common Stock and 1,058,454 shares issuable upon exercise of Warrants, subject to a 9.99% ownership blocker. The filing cites 23,806,216 shares outstanding as of March 30, 2026 used to calculate the reported approximately 9.99% ownership percentage. A Joint Filing Agreement is included.
NeOnc Technologies Holdings reported a larger first-quarter net loss while highlighting serious liquidity risks. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $8.8 million, compared with a $32.3 million loss a year earlier. Cash and cash equivalents were just $138,601 against total liabilities of $16.6 million, leaving a stockholders’ deficit of $13.2 million. Management states that existing capital is not sufficient to fund operations for one year from the financial statement issuance date and that this raises substantial doubt about NeOnc’s ability to continue as a going concern. To support operations, the company relied on equity financing, including a January 2026 private placement that brought in about $13.1 million of gross proceeds and sales under an equity purchase agreement.
NeOnc Technologies Holdings, Inc. filed an amendment to its annual report to add detailed Part III information on leadership, compensation, ownership, related-party dealings, and auditor fees for the year ended December 31, 2025. The filing describes a board with multiple independent directors, formal audit and compensation oversight, and a Code of Ethics and Insider Trading Policy. It outlines executive employment agreements, severance terms, and significant restricted stock grants under the 2023 Incentive Stock Plan, which reserves 4,764,507 shares. As of May 4, 2026, 25,285,530 common shares were outstanding and non‑affiliate equity market value was about $67.9 million.
NEONC Technologies Holdings president Amir F. Heshmatpour reported an open-market purchase of 10,000 shares of Common Stock at $4.1592 per share. After this buy, he directly holds 3,072,000 shares. The filing also lists additional indirect holdings through AFH Holdings & Advisory, LLC, KIG LLC, and HCWG LLC.
Certain shares are held by family members and LLCs, where he disclaims beneficial ownership except for any pecuniary interest described in the footnotes. Overall, this is a relatively small purchase compared with his multi‑million‑share aggregate stake.
NEONC Technologies Holdings, Inc. president and director Amir F. Heshmatpour reported an open-market purchase of 10,000 shares of common stock at $4.518 per share. Following this trade, his direct holdings total 3,062,000 shares of NTHI common stock.
The filing also lists significant indirect holdings, including shares held through AFH Holdings & Advisory, LLC, HCWG LLC, KIG LLC, and certain family members. The report notes that Heshmatpour disclaims beneficial ownership of some of these indirectly held shares except for any pecuniary interest.